SAN DIEGO, CA--(Marketwired - May 1, 2014) - PURE Bioscience, Inc. (
A critical issue for the poultry industry in particular is the stubborn persistence of salmonella through the processing of chicken. Infection from salmonella bacteria is one of the most common sources of food borne illnesses in the US. The US Centers for Disease Control estimates that there are 40,000 cases of salmonellosis annually and that 400 of these result in death.
The extensive testing and evaluation of SDC for direct decontamination of chicken during processing was conducted by Dr. James Marsden, a noted food safety scientist and expert at Kansas State University. The testing evaluated the incorporation of SDC as a component of an integrated food safety system that included existing interventions. The results showed that the combination of treatments has the potential to reduce Salmonella on raw poultry products to levels below the detection limit when SDC is included in the process. An added benefit of using SDC is that it is non-toxic and safe for users (no irritating "off gassing" that is present in many commonly used interventions).
Dr. Marsden is preparing the submissions for the USDA and FDA, which will be made before the end of May. Concurrently, Dr. Marsden is conducting similar testing for direct application of SDC in the processing of produce and meats.
"We are constantly searching for new, more effective technologies that reduce the presence of pathogens in food and, hence, the risk of food borne illness outbreaks," said Dr. Marsden. "The results of our testing conclusively demonstrate that incorporation of SDC in poultry processing would be extremely effective in dramatically reducing salmonella contamination."
Hank Lambert, CEO of PURE Bioscience, said, "The conclusions reached by Dr. Marsden in his rigorous testing and evaluation of SDC clearly demonstrate that SDC-based direct food application results in a material improvement in the killing of pathogens in the processing of poultry. While SDC is already registered with the U.S. EPA and in use for indirect food contact applications, these impressive test results greatly increase the value of the SDC-based food safety solution that PURE is able to offer the food industry. We believe this development could revolutionize the industry and increase the safety of our food supply. We look forward to rapid commercialization upon obtaining regulatory approvals," Lambert concluded.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing its proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control within the food industry. The Company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection. As a platform technology, SDC is distinguished from existing products in the marketplace by its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, including to manufacture its products, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed October 24, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
- Consumer Discretionary
- Health Care Industry
- James Marsden